Ebola Vaccine Shows T Cell Cross-Reactivity Against Bundibugyo Virus

· Science · DR Congo

Researchers report that an existing Ebola vaccine induces T cell cross-reactivity against Bundibugyo virus (BDBV) in humans. The finding comes during the current BDBV outbreak in the Democratic Republic of the Congo, which is the second largest Ebola outbreak worldwide, with more than 6,000 confirmed cases and a 48% fatality rate. No approved vaccine exists specifically for BDBV, so an already-deployed vaccine that generates a cross-reactive immune response could offer a stopgap. The result centers on T cells rather than antibodies, suggesting a cellular immune response that may recognize the related virus. Background: Ebola vaccines have been developed and used against the Zaire species, but protection against other species such as Bundibugyo is not established.

Why it matters：With no approved Bundibugyo vaccine and a large ongoing outbreak, evidence of cross-protection from an existing vaccine could shape how health agencies respond to this and future Ebola species outbreaks.

Key points

  • The current Bundibugyo outbreak has over 6,000 confirmed cases and a 48% fatality rate.
  • There is no approved vaccine specifically for Bundibugyo virus.
  • The reported cross-reactivity involves T cells rather than antibodies.

Sources (original reporting)

More stories from this day